2-(3-pyridyl)-6-(4-pyridyl)pyrimidin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-(3-pyridyl)-6-(4-pyridyl)pyrimidin-4-one
• 英文别名: 2-(3-Pyridyl)-6-(4-pyridyl)pyrimidin-4-one；2-pyridin-3-yl-4-pyridin-4-yl-1H-pyrimidin-6-one
• 化学式: C₁₄H₁₀N₄O
• 分子量: 250.26
• InChiKey: BBOKSECWCAVONN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  异烟酰乙酸乙酯 、 3-甲脒基吡啶盐酸盐 在 potassium carbonate 作用下， 以 乙醇 为溶剂， 反应 20.0h， 以50%的产率得到2-(3-pyridyl)-6-(4-pyridyl)pyrimidin-4-one
  参考文献：
  名称：

  PYRIMIDONE DERIVATIVES

  摘要：

  公开号：

  EP1115721B1

文献信息

• Pyrimidone derivatives
  申请人：Mitsubishi Chemical Corporation

  公开号：US07256199B1

  公开（公告）日：2007-08-14

  A pyrimidone derivative represented by the formula (I) or a salts thereof: wherein R1 represents an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aryl group and the like; R2 represents a hydrogen atom, hydroxyl group, an alkyl group, an alkenyl group and the like, R3 represents a pyridyl group, and a medicament comprising said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as Alzheimer disease.

  一种由公式（I）表示的吡啶酮衍生物或其盐： 其中，R1代表烷基，烯基，炔基，环烷基，芳基等；R2代表氢原子，羟基，烷基，烯基等；R3代表吡啶基。该衍生物或其盐作为活性成分的药物，用于预防和/或治疗由tau蛋白激酶1过度活化引起的疾病，如阿尔茨海默病。
• US7256199B1
  申请人：——

  公开号：US7256199B1

  公开（公告）日：2007-08-14
• [EN] PYRIMIDONE DERIVATIVES<br/>[FR] DERIVES PYRIMIDONE
  申请人：MITSUBISHI CHEM CORP

  公开号：WO2000018758A1

  公开（公告）日：2000-04-06

  A pyrimidone derivative represented by formula (I) or a salts thereof: wherein R1 represents an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aryl group and the like; R2 represents a hydrogen atom, hydroxyl group, an alkyl group, an alkenyl group and the like, R3 represents a pyridyl group, and a medicament comprising said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase l hyperactivity such as Alzheimer disease.